logo-loader
viewCytoDyn Inc.

CytoDyn to begin generating revenue with IncellDX licensing agreement

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive Investors the biotech has executed an exclusive worldwide licensing agreement with cell diagnostic company IncellDX, positioning CytoDyn to generate its first revenue over the next several months

Pourhassan also explains the recent departure of Dr Richard Pestell, former chief medical officer, and what this means for CytoDyn's further clinical development of leronlimab (PRO 140) in cancer treatment and immunology.

Quick facts: CytoDyn Inc.

Price: 3.1 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.49 billion
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn continues to report strong results from COVID-19...

CytoDyn Inc (OTCQB: CYDY) President and CEO Nader Pourhassan and Bruce Patterson, M.D. and Chief Executive Officer and founder of IncellDx joined Steve Darling from Proactive Vancouver with news the company continues to see more impressive results from COVID-19 patients who have received...

3 weeks, 4 days ago

2 min read